trial · primary record
furmonertinib 240 mg oral, daily
Metastatic Non-Small Cell Lung Cancer
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 398 |
| Primary completion | 2028-02-15 |
| Primary endpoint | Progression Free Survival (PFS) determined by blinded independent central review (BICR) |
| Registry ID | NCT05607550 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:47:55.270Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05607550
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.